Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis

被引:33
作者
Chapron, A. [1 ]
Shen, D. D. [1 ,3 ]
Kestenbaum, B. R. [2 ]
Robinson-Cohen, C. [2 ]
Himmelfarb, J. [2 ]
Yeung, C. K. [2 ,3 ]
机构
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
[2] Univ Washington, Dept Med, Div Nephrol, Kidney Res Inst, Seattle, WA 98195 USA
[3] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA
来源
CTS-CLINICAL AND TRANSLATIONAL SCIENCE | 2017年 / 10卷 / 05期
关键词
SINGLE-DOSE PHARMACOKINETICS; IMPAIRED RENAL-FUNCTION; DRUG-DOSAGE; OPEN-LABEL; PHARMACODYNAMICS; INSUFFICIENCY; HEMODIALYSIS; BIOMARKERS; KINETICS;
D O I
10.1111/cts.12481
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Drug-dose modification in chronic kidney disease (CKD) utilizes glomerular filtration rate (GFR) with the implicit assumption that multiple renal excretory processes decline in parallel as CKD progresses. We compiled published pharmacokinetic data to evaluate if GFR predicts renal clearance changes as a function of CKD severity. For each drug, we calculated ratio of renal clearance to filtration clearance (Rnf). Of 21 drugs with Rnf > 0.74 in subjects with GFR > 90 mL/min (implying filtration and secretion), 13 displayed significant change in Rnf vs. GFR (slope of linear regression statistically different from zero), which indicates failure of GFR to predict changes in secretory clearance. The dependence was positive (n = 3; group A) or negative (n = 10; group B). Eight drugs showed no correlation (group C). Investigated drugs were small molecules, mostly hydrophilic, and ionizable, with some characterized as renal transporter substrates. In conclusion, dosing adjustments in CKD require refinement; in addition to GFR, biomarkers of tubular function are needed for secreted drugs.
引用
收藏
页码:395 / 403
页数:9
相关论文
共 51 条
  • [1] Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations
    Aweeka, FT
    Jacobson, MA
    Martin-Munley, S
    Hedman, A
    Schoenfeld, P
    Omachi, R
    Tsunoda, S
    Gambertoglio, JG
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 20 (04) : 350 - 357
  • [2] PHARMACOKINETICS OF FAMCICLOVIR IN SUBJECTS WITH VARYING DEGREES OF RENAL IMPAIRMENT
    BOIKE, SC
    PUE, MA
    FREED, MI
    AUDET, PR
    FAIRLESS, A
    ILSON, BE
    ZARIFFA, N
    JORKASKY, DK
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) : 418 - 426
  • [3] BRENNER B.M., 1976, KIDNEY
  • [4] THE PATHOLOGIC PHYSIOLOGY OF CHRONIC BRIGHTS DISEASE - AN EXPOSITION OF THE INTACT NEPHRON HYPOTHESIS
    BRICKER, NS
    MORRIN, PAF
    KIME, SW
    [J]. AMERICAN JOURNAL OF MEDICINE, 1960, 28 (01) : 77 - 98
  • [5] ON MEANING OF INTACT NEPHRON HYPOTHESIS
    BRICKER, NS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1969, 46 (01) : 1 - &
  • [6] Brody SR, 1999, CLIN PHARMACOL THER, V65, P21, DOI 10.1038/clpt.1999.3
  • [7] The Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol
    Bui, Khanh
    She, Fahua
    Sostek, Mark
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12) : 1375 - 1382
  • [8] Impact of Impaired Renal Function on the Pharmacokinetics of the Antiepileptic Drug Lacosamide
    Cawello, Willi
    Fuhr, Uwe
    Hering, Ursula
    Maatouk, Haidar
    Halabi, Atef
    [J]. CLINICAL PHARMACOKINETICS, 2013, 52 (10) : 897 - 906
  • [9] Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
    Chen, Nionhang
    Lau, Henry
    Kon, Linghui
    Kumar, Gondi
    Zeldis, Jerome B.
    Knight, Robert
    Laskin, Oscar L.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (12) : 1466 - 1475
  • [10] CLERICETTI N, 1991, CLIN NEPHROL, V36, P281